Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Department of Urology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Organ Transplantation and Nephrosis, Shandong Institute of Nephrology, Jinan, Shandong, China.
J Cancer Res Ther. 2024 Aug 1;20(4):1241-1250. doi: 10.4103/jcrt.jcrt_2395_22. Epub 2024 Aug 29.
Papillary thyroid cancer (PTC) is a serious threat to human health worldwide, while metastasis in the early phase limits therapeutic success and leads to poor survival outcomes. The CXC chemokine receptor type 4 (CXCR4) plays an important role in many cellular movements such as transcriptional modulation, cell skeleton rearrangement, and cell migration, and the change in CXCR4 levels are crucial in various diseases including cancer. In this study, we explored the role of CXCR4 in the migration and invasion of PTC and investigated the potential mechanisms underlying its effects.
We analyzed the expression levels of CXCR4 in PTC tissues and cell lines. Would healing migration, Transwell invasion assay in vitro, and tail-vein lung metastasis assay In vivo were performed to evaluated the migration and invasion abilities of PTC cells with stable CXCR4 knockdown or overexpression. Signal transducers and activators of transcription (STAT3) signaling pathway-related protein expressions were examined by Western blotting assays.
The results showed that CXCR4 was highly expressed in PTC cell lines and PTC tissues. CXCR4 knockdown in PTC cells dampened the migration, invasion, and epithelial-mesenchymal transition (EMT), whereas CXCR4 overexpression enhanced these properties. In vivo, we also found that CXCR4 promoted the metastasis of PTC. Mechanistic studies showed that CXCR4 played these vital roles through the STAT3 signaling pathway. Furthermore, PTC patients with high CXCR4 or p-STAT3 expression correlated with aggressive clinical characteristics such as extrathyroidal extension (ETE), and lymph node metastasis (LNM).
We provided evidence that CXCR4 might activate the STAT3 signaling pathway and further promote PTC development. Thus, CXCR4 might be a novel therapeutic target for PTC.
甲状腺乳头状癌(PTC)是全球范围内严重威胁人类健康的疾病,而早期转移限制了治疗的成功并导致不良的生存结果。CXC 趋化因子受体 4(CXCR4)在许多细胞运动中发挥重要作用,如转录调节、细胞骨架重排和细胞迁移,而 CXCR4 水平的变化在包括癌症在内的各种疾病中至关重要。在本研究中,我们探讨了 CXCR4 在 PTC 迁移和侵袭中的作用,并研究了其作用的潜在机制。
我们分析了 PTC 组织和细胞系中 CXCR4 的表达水平。通过稳定敲低或过表达 CXCR4 的体外划痕愈合迁移、Transwell 侵袭实验和体内尾静脉肺转移实验,评估 PTC 细胞的迁移和侵袭能力。通过 Western blot 实验检测信号转导和转录激活因子(STAT3)信号通路相关蛋白的表达。
结果表明,CXCR4 在 PTC 细胞系和 PTC 组织中高表达。PTC 细胞中 CXCR4 的敲低抑制了迁移、侵袭和上皮-间充质转化(EMT),而 CXCR4 的过表达增强了这些特性。在体内,我们还发现 CXCR4 促进了 PTC 的转移。机制研究表明,CXCR4 通过 STAT3 信号通路发挥这些重要作用。此外,PTC 患者中 CXCR4 或 p-STAT3 的高表达与侵袭性临床特征相关,如甲状腺外扩展(ETE)和淋巴结转移(LNM)。
我们提供的证据表明,CXCR4 可能通过激活 STAT3 信号通路进一步促进 PTC 的发展。因此,CXCR4 可能是 PTC 的一个新的治疗靶点。